These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 3871853

  • 1. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Fuller RW, Hemrick-Luecke SK.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW, Robertson DW, Hemrick-Luecke SK.
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [Abstract] [Full Text] [Related]

  • 3. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 4. Effects of amfonelic acid, alpha-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW, Hemrick-Luecke SK.
    Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):17-25. PubMed ID: 3873102
    [Abstract] [Full Text] [Related]

  • 5. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
    Corsini GU, Pintus S, Bocchetta A, Piccardi MP, Del Zompo M.
    J Pharmacol Exp Ther; 1986 Aug; 238(2):648-52. PubMed ID: 3488394
    [Abstract] [Full Text] [Related]

  • 6. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT, Irwin I, Delanney LE, Langston JW.
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [Abstract] [Full Text] [Related]

  • 7. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N, Barneoud P, Carter C, Caille D, Sontag N, Marc C, Lolivier J, Gardes A, Perron C, Le Kim A, Charieras T, Pandini M, Burnier P, Puech F, Jegham S, George P, Scatton B, Curet O.
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [Abstract] [Full Text] [Related]

  • 8. Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
    Fuller RW, Hemrick-Luecke SK.
    Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):147-56. PubMed ID: 3496637
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors.
    Fuller RW, Hemrick-Luecke SK, Robertson DW.
    Res Commun Chem Pathol Pharmacol; 1985 Oct; 50(1):57-65. PubMed ID: 2417293
    [Abstract] [Full Text] [Related]

  • 10. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.
    Itzhak Y, Mash D, Zhang SH, Stein I.
    Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660
    [Abstract] [Full Text] [Related]

  • 11. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW, Hemrick-Luecke SK, Kindt MV, Heikkila RE.
    Life Sci; 1988 Mar; 42(3):263-71. PubMed ID: 3121972
    [Abstract] [Full Text] [Related]

  • 12. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B.
    Walsh SL, Wagner GC.
    Synapse; 1989 Mar; 3(4):308-14. PubMed ID: 2787063
    [Abstract] [Full Text] [Related]

  • 13. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity.
    Kinemuchi H, Arai Y, Toyoshima Y.
    Neurosci Lett; 1985 Jul 31; 58(2):195-200. PubMed ID: 3876524
    [Abstract] [Full Text] [Related]

  • 14. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC.
    Nature; 1985 Jul 31; 311(5985):467-9. PubMed ID: 6332989
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK, Sonsalla PK, Sieber BA, Heikkila RE.
    J Pharmacol Exp Ther; 1989 Jun 31; 249(3):820-8. PubMed ID: 2786564
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.
    Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE.
    J Pharmacol Exp Ther; 1987 Sep 31; 242(3):850-7. PubMed ID: 2888874
    [Abstract] [Full Text] [Related]

  • 17. Primate-rodent 3H-MPTP binding differences, and biotransformation of MPTP to a reactive intermediate in vitro.
    Corsini GU, Pintus S, Bocchetta A, Piccardi MP, Del Zompo M.
    J Neural Transm Suppl; 1986 Sep 31; 22():55-60. PubMed ID: 3097260
    [Abstract] [Full Text] [Related]

  • 18. Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents.
    Fuller RW, Steranka LR.
    Life Sci; 1985 Jan 21; 36(3):243-7. PubMed ID: 3871244
    [Abstract] [Full Text] [Related]

  • 19. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
    Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M.
    J Pharmacol Exp Ther; 1993 Apr 21; 265(1):103-11. PubMed ID: 8473998
    [Abstract] [Full Text] [Related]

  • 20. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR, Zhu XZ, Guan HJ, Wang RG, Ji XQ.
    Zhongguo Yao Li Xue Bao; 1999 Feb 21; 20(2):146-50. PubMed ID: 10437162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.